Archives: 2020-12-10

PIER MARIA FORNASARI
2020-12-10

Human Mesenchymal Stromal Cells Are Resistant to SARS-CoV-2 Infection under Steady-State, Inflammatory Conditions and in the Presence of SARSCoV-2-Infected Cells

Previous studies reported on the safety and applicability of mesenchymal stem/stromal cells (MSCs) to ameliorate pulmonary inflammation in acute respiratory distress syndrome (ARDS). Thus, multiple clinical trials assessing the potential of MSCs for COVID-19 treatment are underway. Yet, as SARS-inducing coronaviruses infect stem/progenitor cells, it is unclear whether MSCs could be infected by SARS-CoV-2 upon

Read More

No Comments InCELL THERAPY
PIER MARIA FORNASARI
2020-12-10

Real-life validation of the Panbio™ COVID-19 antigen rapid test (Abbott) in community-dwelling subjects with symptoms of potential SARS-CoV-2 infection

RT-qPCR is the reference test for identification of active SARS-CoV-2 infection, but is associated with diagnostic delay. Antigen detection assays can generate results within 20 min and outside of laboratory settings. Yet, their diagnostic test performance in real life settings has not been determined. The diagnostic value of the Panbio™ COVID-19 Ag Rapid Test (Abbott),

Read More

2 comments InCovid-19
PIER MARIA FORNASARI
2020-12-10

COVID-19’s sex bias based on a large-scale global statistical analysis: men more at risk of requiring critical care

Sex should be considered an important biological factor when designing therapies and vaccination strategies for COVID-19. Global-scale collaboration between scientists has taken on new forms in the midst of the COVID-19 pandemic, with connection underpinning the work. A paper investigating the role of sex in patients infected with COVID-19 is the result of a partnership between researchers

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2020-12-09

Researchers at Gladstone Institutes Identify Critical Molecules that Coronaviruses Hijack to Infect Human Cells

When a coronavirus—including SARS-CoV-2, which causes COVID-19—infects someone, it hijacks the person’s cells, co-opting their molecular machinery for its own survival and spread. Researchers at Gladstone Institutes and the Chan Zuckerberg Biohub, in collaboration with scientists at UC San Francisco (UCSF) and Synthego Corporation, have identified critical molecular processes in human cells that coronaviruses use

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2020-12-08

3D VR video on CAR-T therapy to learn more about how this innovative technology is being used to tackle MultipleMyeloma.

The Janssen Pharmaceutical Companies of Johnson & Johnson  unveils longer-term results from the combined Phase 1b/2 CARTITUDE-1 study evaluating ciltacabtagene autoleucel (cilta-cel) for the treatment of patients with relapsed and/or refractory multiple myeloma. Cilta-cel is an experimental BCMA-directed (B cell maturation antigen) chimeric antigen receptor T cell (CAR-T) therapy. Data presented at the ongoing Annual Meeting

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2020-12-08

Oxford–AstraZeneca COVID-19 vaccine efficacy: an interim analysis of four randomised controlled trials in Brazil, South Africa and the UK published on The Lancet

2020 has been a difficult year for all, but has seen 58 vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) be developed and in clinical trials, with some vaccines reportedly having more than 90% efficacy against COVID-19 in clinical trials. This remarkable achievement is much-needed good news as COVID-19 cases are currently at their

Read More

No Comments InCovid-19
PIER MARIA FORNASARI
2020-12-05

Presented CAR T ZUMA-5 phase 2 study data for non-Hodgkin lymphoma

Earlier this year, Caron Jacobson, MD, presented the interim analysis of ZUMA-5: A phase 2 study of axicabtagene ciloleucel in patients with relapsed/refractory indolent non-Hodgkin lymphoma. Results from that interim analysis showed that the vast majority of patients with follicular lymphoma or marginal zone lymphoma – two slow-growing forms of non-Hodgkin lymphoma – responded to and

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2020-12-04

Moderna mRNA-1273 Vaccination produced serum neutralizing antibodies detected in all the participants at day 119

Vaccine “has the potential to provide durable humoral immunity” against virus, NIAID authors argue Antibody responses to Moderna’s COVID-19 vaccine candidate, mRNA-1273, remained strong for almost 4 months following vaccination, data from a phase I trial indicated. Serum neutralizing antibodies were detected in 34 healthy adult volunteers at day 119 following the first dose, and

Read More

No Comments InCovid-19